Active hepatitis B or hepatitis C infection
Participants with active hepatitis B or hepatitis C
Known active viral or nonviral hepatitis or cirrhosis
Patients with untreated or active hepatitis B or C infection
Active hepatitis B or hepatitis C with abnormal liver function tests
Patients with known hepatitis B or hepatitis C are not eligible, regardless of concomitant antiretroviral therapy or current viral load
Patients with known human immunodeficiency virus (HIV) disease taking antiretroviral therapy are excluded\r\n* Patients with known chronic active hepatitis B (defined as a positive hepatitis B surface antigen and/or hepatitis B viral load in the last 12 months) are excluded, regardless of antiviral treatment
Patients with known active hepatitis B or C
Recent history of hepatitis infection or if the treating physician determined that the patient would be at significant risk of reactivation of hepatitis
Patients with known active hepatitis (i.e. hepatitis B or C)
Liver disease including history of viral hepatitis B or C, evidence of cirrhosis, chronic active or persistent hepatitis
Known history of hepatitis C infection or suspected currently active hepatitis C infection; known or suspected history of hepatitis B infection will be excluded when any of the following conditions are met:\r\n* Received hematopoietic stem cell transplantation (either allogenic or autologous), or\r\n* Received any rituximab-containing treatment regimen in the last 12 months before entering the study, or\r\n* Active hepatitis B as deemed by serology or viral load
Positive hepatitis C serology or active hepatitis B infection; chronic asymptomatic viral hepatitis is allowed
Patients with known active hepatitis B or C; baseline testing is not required
Active hepatitis B or hepatitis C
Must have Child-Pugh A only. Participants may have any viral status (hepatitis B, hepatitis C, or none).
Patients with clinically active hepatitis A, B, or C infections are not eligible\r\n* Note: patients with a history of hepatitis may be eligible if they have a normal titer; such cases should be approved by the study principal investigator (PI)
Patients with a known history of infection with hepatitis B or hepatitis C virus (active, previously treated, or both) will not be eligible due to the increased risk of hepatotoxicity and viral reactivation associated with systemic chemotherapy
Patients must not have a history of chronic or active hepatitis B or C infection; patients must have negative hepatitis B and C serologies performed within 28 days prior to registration
Active hepatitis B infection
Active hepatitis C infection
Subject with seropositivity for hepatitis B or hepatitis C must be cleared by hepatology service prior to participating in treatment protocol
Active hepatitis A, B, or C infection.
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Positive for Hepatitis C or Chronic Hepatitis C.
Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR)
Active or chronic viral hepatitis B or C infection
Active hepatitis B viral infection (defined as HBsAg+).
Participants with active chronic or acute hepatitis C or B infection
Known infection with HIV, hepatitis B, or hepatitis C
Active or chronic hepatitis B or hepatitis C.
Known active or chronic hepatitis B or C infection or HIV
Patients who have HIV, Hepatitis B or C
Has a known history of hepatitis B and/or hepatitis C infection
Active hepatitis B or C or a history of HIV infection
Patient has known active hepatitis B infection (defined as presence of hepatitis B surface antigen [HepB sAg] and/ or hepatitis B [Hep B] deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of Hep C RNA) and/or known human immunodeficiency virus (HIV); patients with HIV who have a normal CD4 count (>= 200) and an undetectable viral load are not excluded
Active or chronic hepatitis B or C infection\r\n* Previously infected with evidence of immunity and no evidence of active hepatitis is not an exclusion criterion
Known active hepatitis B and/or C
Patients with known hepatitis B or C; screening for hepatitis B and/or C is not required for eligibility for this study
Patients with cirrhosis, or active viral or nonviral hepatitis
Chronic or active hepatitis B or C, requiring antiviral therapy
Known active hepatitis A, B or C
Active hepatitis B and/or hepatitis C infection
Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.
Active hepatitis B or hepatitis C
Patients with known (testing is not part of the protocol) active hepatic disease (i.e., hepatitis B or C) due to risk of drug interactions with anti-viral therapy
Positive serology for hepatitis B or hepatitis C or known HIV infection
Known history of HIV, hepatitis C or hepatitis B infection
Known history of HIV, hepatitis B, or hepatitis C infection
Active Hepatitis B or C infection
Prior to start of everolimus, the following three categories of patients should be tested for hepatitis B viral load and serologic markers, that is, HBV-DNA, HBsAg, hepatitis B surface (HBs) antibody (Ab), and hepatitis B core (HBc) Ab\r\n* All patients who currently live in (or have lived in) Asia, Africa, Central and South America, Eastern Europe, Spain, Portugal and Greece\r\n* Patients with any of the following risk factors:\r\n** Known or suspected past hepatitis B infection,\r\n** Blood transfusion(s) prior to 1990,\r\n** Current or prior intravenous (IV) drug users,\r\n** Current or prior dialysis,\r\n** Household contact with hepatitis B infected patient(s),\r\n** Current or prior high-risk sexual activity,\r\n** Body piercing or tattoos,\r\n** Mother known to have hepatitis B\r\n** History suggestive of hepatitis B infection, e.g., dark urine, jaundice, right upper quadrant pain\r\n** Additional patients at the discretion of the investigator
Patients with any of the following risk factors for hepatitis C should be tested using quantitative RNA-polymerase chain reaction (PCR):\r\n* Known or suspected past hepatitis C infection (including patients with past interferon ‘curative’ treatment),\r\n* Blood transfusions prior to 1990,\r\n* Current or prior IV drug users,\r\n* Current or prior dialysis,\r\n* Household contact of hepatitis C infected patient(s),\r\n* Current or prior high-risk sexual activity,\r\n* Body piercing or tattoos\r\n* At the discretion of the investigator, additional patients may also be tested for hepatitis C
Hepatitis B or C
History of Hepatitis B, C, or HIV
Known active hepatitis B or C
Active hepatitis A, B, or C infection
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
History of hepatitis B
A history of active hepatitis B and/or hepatitis C infection
Patients who have known active hepatitis B or C
Participants with known active or chronic infection with hepatitis B or C.
Has a known history of Hepatitis B or Hepatitis C.
Participants with known positive test for hepatitis B or C indicating acute or chronic infection
Known to be positive for HIV or hepatitis B, or known to have active hepatitis C infection
Has known active Hepatitis B or known active Hepatitis C virus infection.
Participant has known infection with hepatitis B or hepatitis C.
Known active hepatic disease (ie, Hepatitis B or C)
Known active Hepatitis B or Hepatitis C
Participants with known active hepatitis B or hepatitis C
Has a known history of hepatitis B or known active hepatitis C virus infection
Active hepatitis B and hepatitis C virus infection
ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients with known active hepatitis B and/or active hepatitis C infection
Patients with known active Hepatitis B or Hepatitis C infection
Participants with known acute or chronic hepatitis B or hepatitis C
Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR)
Participants with known active hepatitis B or C
Known active HIV, hepatitis B or hepatitis C, where active is defined as follows:
Known active Hepatitis B or C
Hepatitis B or C
Known hepatitis B surface antigen-positive or known or suspected active hepatitis C infection.
Active hepatitis B or C (testing required).
Known active hepatitis B or C or known infection with HIV
Active hepatitis B or hepatitis C
Patients with history of hepatitis B and hepatitis C will be eligible but patients with hepatitis B must be started on antiviral therapy prior to beginning study therapy
Has known active Hepatitis B or C. Active Hepatitis B.
Patient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)
Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis C
Known active hepatitis B or hepatitis C
Known history of active tuberculosis (TB), autoimmune disease, pneumonitis, infection, HIV, Hepatitis B, or Hepatitis C
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Positive for Hepatitis C or chronic Hepatitis C
Known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen [sAg] and/or Hep B deoxyribonucleic acid [DNA]), known active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier
Chronic active Hepatitis B or C.
History of chronic hepatitis B or C
Patients with known active Hepatitis C, HIV or a present history of Hepatitis B
Active hepatitis B (HBV) or hepatitis C (HCV) infection
Active hepatitis A, hepatitis B, or hepatitis C infection
Known active hepatitis A, B, or C
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Patients with cirrhosis, or active viral or nonviral hepatitis
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Active hepatitis B or C infection
Hepatitis B or HIV infection
Patients with hepatitis B infection must be on appropriate antiviral therapy
Active hepatitis B or C infection
Known active hepatitis B or C
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Has evidence of acute or chronic hepatitis B or hepatitis C
Known diagnosis of active hepatitis B or hepatitis C
Subject has a diagnosis of chronic active hepatitis B or C.
Active hepatitis B or active hepatitis C;
Active hepatitis B, hepatitis C at the time of screening
Known hepatitis B or hepatitis C infection
Evidence of active Hepatitis B, active Hepatitis C infection (HCV) or cytomegalovirus (CMV) or known history of HIV.
Patients with active viral hepatitis.
Subjects with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Active infections including hepatitis B carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [hep] B and hep C viral load at screening)
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction
Active hepatitis B or C infection
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have known active hepatitis B, or hepatitis C infections
COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients who have known active hepatitis B, or hepatitis C infections
COHORT 3: ENDOMETRIAL CANCER: Patients who have known active hepatitis B, or hepatitis C infection
Chronic, active, or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
Patients with known active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; patients with a history of hepatitis B or hepatitis C, who are deemed cured and no longer require treatment may be allowed to enroll after consultation with the respective specialist and the study PI
Active Hepatitis C infection. Subjects who have been treated for Hepatitis C infection can be included if they have documented sustained virologic response of ? 12 weeks.
Active or chronic viral hepatitis B or C infection Exclusions Related to Ocular Disease
Has known active hepatitis B or hepatitis C virus infection.
Active ongoing infection requiring therapy; patients with known chronic hepatitis C infection will be allowed if antiviral therapy is not in use; patients with evidence of chronic hepatitis B infection as evidenced by hepatitis B surface antigen positivity and/or evidence of hepatitis B circulating deoxyribonucleic acid (DNA) are required to receive viral prophylaxis while on treatment with entecavir or tenofavir per institutional guidelines; hepatitis viral load studies will be followed as described in protocol
Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
Active hepatitis B, hepatitis C at the time of screening
No active hepatitis or diagnosis of HIV disease.
Known active hepatitis infection
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Subject has active infectious hepatitis, type A, B, or C, or chronic carriers of hepatitis C.
Subjects with known HIV or active viral hepatitis
Known active hepatitis B or C
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Active infection including hepatitis B-carrier status, hepatitis C virus (HCV) infection (patients must have a negative hepatitis [Hep] B and Hep C viral load at screening)
Known active viral or nonviral hepatitis or cirrhosis
Active hepatitis A, hepatitis B, or hepatitis C infection
Active hepatitis B or hepatitis C infection
Active hepatitis B infection as documented by positive hepatitis B polymerase chain reaction (PCR) assay
Active hepatitis B. Patients with chronic hepatitis B who are on appropriate viral suppressive therapy may be allowed after discussion with the principal investigator (PI).
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Known positivity for hepatitis B or C
Has an active bacterial, fungal, and/or known viral infection; patients with known human immunodeficiency virus (HIV) infection are excluded given the potential for interactions between antiretroviral agents and abemaciclib, and the potential for increased risk of life threatening infection with therapy that is myelosuppressive; patients with known hepatitis B or hepatitis C infection are excluded only if there is evidence of active infection (detectable hepatitis B surface antigen, detectable hepatitis C ribonucleic acid [RNA])
Patients who are carriers of hepatitis virus B and C; hepatitis B and C testing must be performed to confirm status prior to enrollment
History of hepatitis B or C or chronic hepatitis
Known to be positive for HIV, Hepatitis B, or Hepatitis C
Known HIV, Hepatitis A, B or C infection.
Active hepatitis B or C infection
Known hepatitis B or hepatitis C with abnormal liver function tests
Patients with positive hepatitis serology that is definitive of active disease.
Patients with chronic active hepatitis or cirrhosis. If positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy.
Active hepatitis A, B or C infection
Clinically active infection with hepatitis B or hepatitis C virus
Active infection with hepatitis B; active or chronic infection with hepatitis C
Patient has known active hepatitis B infection (defined as presence of hepatitis B [HepB] surface antigen (sAg) and/ or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) carrier (HIV 1/2 antibodies)
Prior or ongoing liver disease including known cirrhosis, active hepatitis B or C infection; not to exclude patients with a distant history of resolved hepatitis A infection
Patients with a known history of hepatitis B or hepatitis C
Known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Known history of chronic hepatitis B or C
Patients with known active hepatitis (i.e. Hepatitis B or C)
Positive test results for chronic hepatitis B and hepatitis C infection
All participants will be required to be screened for hepatitis C; if hepatitis C antibody positive, with or without a positive hepatitis C RNA level, participants will be permitted to enroll in the study provided liver function tests meet criteria listed, and have no evidence of cirrhosis; participants diagnosed with hepatitis C less than 6 months from trial enrollment will be considered to have acute hepatitis C, and will be excluded from study UNLESS hepatitis C viral load is undetectable
Be undergoing treatment for acute or chronic hepatitis C.
Known human immunodeficiency virus or hepatitis C infection only if the patient is taking medications that are excluded per protocol, active hepatitis B, or active hepatitis C infection.
Patients with known active hepatitis B or hepatitis C
Chronic active or active viral hepatitis A, B, or C infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
On treatment for hepatitis B or hepatitis C or history of tuberculosis (TB)
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Active tuberculosis or hepatitis, or history of hepatitis B or C, or chronic hepatitis
Known hepatitis B or hepatitis C infection; EXCEPTION: if viral load < 800,000 IU/L
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Active hepatitis B or C infection
Known active viral hepatitis, HIV or chronic liver disease.
Known active infection with HIV, hepatitis B, hepatitis C
Patients known to be HIV positive or have active viral hepatitis.
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Subjects must not have a history of any positive test for hepatitis B or hepatitis C indicating active disease or previous exposure
Uncontrolled hepatitis B or C infection
Has a known active hepatitis B or hepatitis C.
Active hepatitis B or C infection
Known active hepatitis B or C
Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient’s participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator; this includes known active tuberculosis; grade 3 active infection; history of allogeneic bone marrow transplant or solid organ transplant; known history of human immunodeficiency virus (HIV); known active hepatitis B (eg, hepatitis [Hep] B deoxyribonucleic acid [DNA] positive in prior 3 months) or known active hepatitis C (eg, hepatitis C virus [HCV] ribonucleic acid [RNA] [qualitative] is detected in prior 3 months)
Known to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)
Patients cannot have previously been treated with interferons (e.g., for chronic active hepatitis)
Hepatitis C on protease therapy
Known history of hepatitis C or known active hepatitis B infection
Active hepatitis B or hepatitis C treatment
No active infection with Hepatitis B.
No active infection with Hepatitis C.
Known hepatitis B or C infection
Has known hepatitis B or hepatitis C
Known or chronic hepatitis C and/or B infection
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Patients with active hepatitis B and C
Pre-existing viral hepatitis
Patients with known active hepatitis B, or hepatitis C will be excluded
Active, uncontrolled infection including known hepatitis B or C
Known or suspected active hepatitis B or C infection
Chronic infection with hepatitis B or hepatitis C virus
Idelalisib\r\n* Ongoing drug-induced liver injury, chronic active hepatitis C (hepatitis C virus [HCV]), chronic active hepatitis B (hepatitis B virus [HBV]), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis\r\n* Ongoing symptomatic pneumonitis\r\n* Ongoing inflammatory bowel disease or autoimmune colitis\r\n* Ongoing cytomegalovirus (CMV) infection, treatment, or prophylaxis within the past 28 days prior to the screening test for active CMV\r\n* History of serious allergic reaction including anaphylaxis and epidermal necrolysis
Ruxolitinib\r\n* Chronic active hepatitis C (HCV)
Active or chronic hepatitis B infection
Patients with acute hepatitis or active infection that requires parenteral antibiotics
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis\r\nC infection
Known active hepatitis B or C infection, or HIV infection.
Known active or symptomatic viral hepatitis or chronic liver disease
History of chronic hepatitis B or C
Has active hepatitis B or C. Patients with serologic evidence of prior exposure are eligible.
Active infection with hepatitis B or hepatitis C virus
Patients with a known history of hepatitis B or hepatitis C are not eligible
Patients with active B or C hepatitis.
Patients who have active infectious hepatitis
Active hepatitis B or hepatitis C infection
Active HIV or hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Known active hepatitis B or C
Active hepatitis, including but not limited to viral and drug-induced
Active hepatitis B or hepatitis C infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Active hepatitis B or active hepatitis C
Known history of HIV disease, active hepatitis B or hepatitis C.
Participants with active hepatitis A, B or C infection.
Known active hepatitis B and/or hepatitis C infection
Known active viral or other chronic types hepatitides (hepatitis B, C) or cirrhosis
Active hepatitis B or active hepatitis C
Known history of Hepatitis B or C or HIV
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Patients tested positive for hepatitis B or with a known, active hepatitis C infection
Known active Hepatitis B or C infection
Evidence of active infection by hepatitis B and/or C; for patients with hepatitis B treated with anti-virals to undetectable viral load, and for patients with hepatitis C with undetectable ribonucleic acid (RNA) levels and no evidence of liver damage, enrollment may be considered and should discuss first with study’s principal investigator
Subjects with known active acute hepatitis
Patients with a known history of hepatitis B or C
Negative for hepatitis A, B, or C infection
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Patients with hepatitis B infection must be on appropriate antiviral therapy
Known active viral or nonviral hepatitis or cirrhosis
Patients with active hepatitis B or C infection (not including patients with prior hepatitis B vaccination); these patients should be cleared by gastrointestinal (GI) consultation for hepatitis B and infectious disease consult for hepatitis C
Known active hepatitis B virus hepatitis, or known active hepatitis C virus
Has a known active hepatitis B or hepatitis C
Known to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)
Chronic hepatitis infection, including B and C
Has uncontrolled HIV or hepatitis B or C
Patients with a positive history of hepatitis B or hepatitis C
Active hepatitis B or C viral infection or hepatitis B surface antigen positive
No evidence of chronic active hepatitis or cirrhosis
Known hepatitis B surface antigen-positive, known or suspected active hepatitis C infection (testing not required).
Known or active hepatitis B or C with abnormal liver function tests
Known active or chronic hepatitis B or C infection
Patients with history of active hepatitis B or C infection or chronic hepatitis with Child Pugh B or C hepatic dysfunction
Active hepatitis B or hepatitis C with abnormal liver function tests; HIV positive patients receiving antivirals.
Baseline hepatitis titers without evidence of acute/active hepatitis
Active hepatitis
Patients with known history of hepatitis B surface antigen-positive, or known history or suspected active hepatitis C infection are not to be enrolled in the study
Presence of any other active or suspected acute or chronic uncontrolled infection or known symptomatic active hepatitis B or C
Patients with hepatitis B and/or hepatitis C infection are excluded if they are on any of the following viral suppressive agents: boceprevir (Victrelis), ribavirin (Rebetol, Ribatab, Ribasphere), telaprevir (Incivek)\r\n* Note: patients with active hepatitis B infection must be on treatment with viral suppressive therapies; these agents may include the following: adefovir (Hepsera), entecavir (Baraclude), lamivudine (Epivir-HBV), telbivudine (Tyzeka), and/or tenofovir (Viread)
Serologic or clinical evidence of current active hepatitis B or C infection, defined as elevated levels of hepatitis (Hep) B antigen or Hep C antibody (unless active infection is ruled out by nucleic acid tests)
Acute or chronic hepatitis B or C infection
Patients with active hepatitis B and/or hepatitis C infection
Active uncontrolled infection, including known history of acquired immune deficiency syndrome (AIDS) or hepatitis B or C
Evidence of acute or chronic active hepatitis or cirrhosis
History of chronic hepatitis B or C
Patients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.
Uncontrolled active hepatitis B or active hepatitis C
Active hepatitis B or hepatitis C infection
Known active hepatitis B or C infection
Any history of hepatitis B infection
Patient with known active infection with HIV, hepatitis B or hepatitis C
History of chronic or active hepatitis
Known HIV positive or active hepatitis B or C
Must not have known active or clinically significant hepatitis A, B or C infection.
Patients with cirrhosis, or active viral or non-viral hepatitis
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Presence of an active acute or chronic infection including: a urinary tract infection as determined by their physician, HIV (as determined by enzyme-linked immunosorbent assay [ELISA] and confirmed by Western blot) or viral hepatitis (as determined by hepatitis B surface antigen [HBsAg] and hepatitis C serology)
Relapsed/refractory MCL: Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Newly diagnosed MCL: Known HIV infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum Hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation
No evidence of chronic active hepatitis or cirrhosis
Chronic hepatitis B or hepatitis C infection
Patients with known active hepatitis B or C, or HIV infection.
Known HIV, Hepatitis B, or Hepatitis C.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Patient has known history of active hepatitis A, B, or C
Active hepatitis B or C viral infection or hepatitis B surface antigen positive
Patients with active hepatitis B and/or hepatitis C infection
Active hepatitis B or C infection
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Known positivity for hepatitis B infection
Known active hepatitis C infection
Patients with active hepatitis are excluded
History of chronic or active hepatitis
Evidence of infection with HIV, hepatitis B or hepatitis C; patients must be HIV negative, hepatitis B surface antigen, and hepatitis C antibody negative; the high degree of immune suppression that may be used in this study may lead to the activation or progression of these viral illnesses
History of chronic or active hepatitis
Patients with a history of hepatitis B with persistent infection.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients who either show chronic hepatitis C or positive hepatitis C serology
Patient who has active Hepatitis B
Known Hepatitis B Ag positive, Hepatitis C positive patients
Patient has active hepatitis B
Has a prior history of viral hepatitis (B or C) as demonstrated by positive serology (presence of antigens) or have an uncontrolled infection requiring treatment. Participants with a known prior history of hepatitis B or C may be eligible pending agreement with the sponsor.
Chronic or active hepatitis B or C if not controlled by antiviral therapy
Active infection requiring systemic therapy, known infection of HIV, Hepatitis B, or Hepatitis C.
Positive hepatitis C serology or active hepatitis B infection
Known HIV infection or active Hepatitis B or Hepatitis C virus infection
Acute or chronic hepatitis B or hepatitis C.
Patients with known HIV, hepatitis B or C;
Patients with active Hepatitis B infection (HBsAg positive) that are not receiving antiviral treatment are excluded
Active hepatitis A or B.
Has known active Hepatitis B or Hepatitis C.
Active hepatitis A or B.
Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to Hepatitis B or C without evidence of active infection may be allowed.
Subject has known active hepatitis B or hepatitis C infection.
Patients who have a known history of hepatitis C or chronic active hepatitis B or a known diagnosis of HIV
Active HIV, hepatitis B or C
Patients must not have a history of HIV, or active Hepatitis A, B, and C.
A history of known, active hepatitis
Patient is known to be hepatitis B surface antigen-positive or has known active hepatitis C infection.
Patients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy
Prior, current, or chronic hepatitis B or hepatitis C infection
Active hepatitis B or C or other active liver disease.
Active hepatitis B or hepatitis C infection at the time of screening
Patients with non-hepatocellular carcinoma must not have acute or chronic hepatitis B or hepatitis C infection
HPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Known infection with hepatitis B, hepatitis C, or HIV
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Patients with known active hepatitis (i.e., hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Known history of Hepatitis B or known active Hepatitis C virus.
Known HIV or chronic Hepatitis B or C infection.
Serologic status reflecting active hepatitis B or C infection.
Active viral hepatitis infection. Subjects with history of hepatitis infection that is not active are eligible.
Patients known to be have active hepatitis B or C; (hepatitis B positive patients are allowed if they are on appropriate antiviral agents such as lamivudine)
Active hepatitis B or hepatitis C infection
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Active hepatitis B or active hepatitis C.
Known acute viral hepatitis
Active hepatitis B or C infection
Known hepatitis (hep) B or C, or known cirrhosis (screening for viral hepatitis is not required)
Active viral hepatitis.
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology.
Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease. These patients should be optimized by GI consultation for hepatitis B and infectious disease consult for hepatitis C.
Known human immunodeficiency virus (HIV) infection. Patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody). Known hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation.
Has known active hepatitis B or hepatitis C infection
Active hepatitis B, hepatitis C
Subjects with a history of chronic or acute hepatitis C or B infection.
History of chronic hepatitis B or C infection
Known active or chronic hepatitis B or C infection or HIV
Be undergoing treatment for acute or chronic hepatitis C.
Known active HIV, HBV, or HCV infection. Inactive hepatitis carrier status or low viral hepatitis titer on antivirals is allowed.
Known active hepatitis B or active hepatitis C infection; participants who have prior hepatitis C infection but who have received an antiviral treatment and show no detectable viral ribonucleic acid (RNA) for 6 months after completion of treatment are eligible
Known history of or positive test for hepatitis B or hepatitis C infection.
Patients with known acute or chronic hepatitis B or hepatitis C infection are ineligible
Known active hepatitis B or C infection or HIV infection.
Patients with known untreated hepatitis C
History of chronic hepatitis B or C
Hepatitis B and C negative
Known hepatitis B or C
Patients with known active hepatitis (i.e. hepatitis B or C)
Chronic active untreated hepatitis B or C infection
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
DONOR: Evidence of active infection or viral hepatitis
Active infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to enrollment
Seropositive for any of the following: HIV ab, hepatitis B sAg, hepatitis (hep) C immunoglobulin (Ig)G Ab positive, without definitive therapy for hepatitis C; or hepatitis C PCR positivity; or hepatitis C IgM positivity
DONOR: Evidence of active infection or viral hepatitis
History of chronic hepatitis B or C
Active hepatitis B or C infection
Positive hepatitis C serology or active hepatitis B infection
Known, active hepatitis A, B, or C infection
Patients who have any known history of liver disease, autoimmune hepatitis, sclerosing cholangitis or are found to be carriers (active disease or not) of hepatitis B and hepatitis C
Active viral hepatitis or autoimmune hepatitis; the work-up to confirm active hepatitis or autoimmune hepatitis will only be done if clinical suspicion based on investigator discretion
Chronic hepatitis C based on the judgment of the investigator
Co-infection with hepatitis B
Patients with known hepatitis B or hepatitis C (active or carriers)
Known active hepatitis A, B, or C infection that requires treatment
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Active infection with hepatitis B; active or chronic infection with hepatitis C
Active hepatitis A, B or C infection\r\n* Hepatitis A serology is not required for normal liver function
Chronic hepatitis infection, including B and C
Active hepatitis B or hepatitis C with abnormal liver function tests
Patients with known hepatitis B or hepatitis C infection must have viral load < 800,000 IU/L within 28 days prior to registration
Known positive hepatitis C serology or active hepatitis B infection – chronic asymptomatic viral hepatitis is allowed
Patients with hepatitis C antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis
Chronic hepatitis infection, including B and C
Known Active hepatitis B or C
Patients with evidence of hepatitis B or hepatitis C PCR positivity
Patients with known active hepatic disease (i.e., hepatitis B or C)
Known HIV positive or active hepatitis B or C, or presence of hepatitis B surface\n             antigens or presence of hepatitis C antibody
Known HIV-, hepatitis B-, or hepatitis C-positive patients (active, previously treated, or both)
Active hepatitis including hepatitis B or C
Active hepatitis B or C infection
History of active hepatitis B or C
Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
Patients who have chronic hepatitis B or hepatitis C
Patients with active hepatitis B or active hepatitis C infection
Patients with hepatitis B
Patients with acute hepatitis or active infection that requires parenteral antibiotics
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and LAI
Patients must not have a known history of active hepatitis B infection (defined as presence of hepatitis B surface antigen [Hep B sAg] and/ or Hep B deoxyribonucleic acid [DNA]), active hepatitis C infection (defined as presence of hepatitis C [Hep C] ribonucleic acid [RNA]) and/or known human immunodeficiency virus (HIV) seropositive
Subject has active hepatitis B or C, or other active hepatic disorder.
Active systemic hepatitis infection requiring treatment (carriers of hepatitis virus are permitted to enter the study), of any type or known acute or chronic liver disease including cirrhosis
Known HIV, active hepatitis B or active hepatitis C infection
Subject with known active HIV, Hepatitis B, or Hepatitis C infections.
Has known active Hepatitis B or Hepatitis C
Known active Hepatitis B or C
Active hepatitis B or C infection
Has known active hepatitis B or hepatitis C.
Has known history of or is positive for Hepatitis B or Hepatitis C
Known active hepatitis B or hepatitis C
Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
Current or active tuberculosis, hepatitis B, or hepatitis C.
Known to be positive for HIV or known to have active hepatitis B or C.
Active replication of or prior infection with hepatitis B or active hepatitis C( HCV RNA positive )
Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection
Active hepatitis B or active hepatitis C
Clinically active infection with hepatitis B or hepatitis C virus
History of hepatitis (B or C)
Known history of HIV seropositivity, hepatitis C virus, acute or chronic active hepatitis B infection, or other serious chronic infection requiring ongoing treatment
Active hepatitis B or C virus infection or active tuberculosis
HIV/active Hepatitis B or C infection
Known active viral or nonviral hepatitis or cirrhosis
Active hepatitis B or C infection based on screening blood testing
Has known history of Hepatitis B or known active Hepatitis C.
Patients must not have known HIV, hepatitis B or hepatitis C positivity
Active coinfection with both hepatitis B (i.e., HBVsAg and/or hepatitis B DNA) and hepatitis C (i.e., hepatitic C RNA)
Hepatitis D infection in subjects with hepatitis B
History of active or chronic hepatitis (e.g. Hep B or C)
Has known active Hepatitis B or C.
Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
Active hepatitis B, hepatitis C, or tuberculosis
Known history or evidence of active hepatitis A, B, or C or HIV
Known positive HIV infection, or active hepatitis B or C infection
Active tuberculosis or recent (< 2 week ago) clinically significant infection or evidence of active hepatitis B, hepatitis C or HIV infection.
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
Baseline hepatitis tiers without evidence of active hepatitis
Active hepatitis
Has known active Hepatitis B or Hepatitis C infection.
Active or chronic infection of hepatitis B virus or hepatitis C
Recent (< 1 week ago) clinically significant infection, active tuberculosis or evidence of active hepatitis B, hepatitis C or HIV infection
History of chronic hepatitis B infection or positive test results for active or chronic hepatitis B or hepatitis C
Known history of HIV infection or a known history of or is positive for Hepatitis B or Hepatitis C
Patients must not have liver disease such a cirrhosis, chronic active hepatitis or chronic persistent hepatitis
No active infection with hepatitis B
No active or chronic infection with hepatitis C
Has known history of Chronic Hepatitis B or C
Active hepatitis B or hepatitis C
Active hepatitis B infection as determined by hepatitis B surface antigen.
Known active hepatitis B or hepatitis C infection.
Patients with known active hepatitis or HIV.
Known to have active hepatitis C infection (positive by polymerase chain reaction) or on antiviral therapy for hepatitis C within 6 months prior to the first doses of brentuximab vedotin and lenalidomide
Subject with a known history of active chronic HIV, hepatitis B or hepatitis C infections; negative hepatitis C viral load is allowed
Active Hepatitis B or C
Current infection with HIV, Hepatitis B or Hepatitis C. Patients will have serologic testing performed during screening for HIV and Hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient's status.
Known HIV or hepatitis B or C viral infection
A diagnosis of active hepatitis B or C
Known active viral or nonviral hepatitis or cirrhosis
Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/L within 28 days prior to registration
Known active hepatitis, type A, B or C; patients who are seropositive because of hepatitis B virus vaccine are eligible
Negative screening tests for hepatitis B and hepatitis C; patients with positive results that do not indicate true active or chronic infection may enroll after discussion and consensus agreement by the treating physician and principal investigator
Hepatitis B or C infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection.
Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months
Has known active Hepatitis B or Hepatitis C
Known infection with hepatitis B, hepatitis C, or HIV.
Known history of active hepatitis B or hepatitis C infection
Active or latent virus disease (HIV, hepatitis B and hepatitis C)
Diagnosis of infection with HIV or chronic infection with hepatitis B or C
Patients known to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)
Active hepatitis B or hepatitis C
Active hepatitis B or hepatitis C infection
Known infection with hepatitis B, C or HIV
Hepatitis B or C infection
known or suspected past hepatitis B infection,
mother known to have hepatitis B
Known disease or history of active or chronic hepatitis C and/or B infection
Patients with liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis, or patients with defined elevated ALT/ AST/ Bilirubin.
Active hepatitis B infection, active hepatitis C infection or known HIV carrier.
Known history of or is positive for Hepatitis B or Hepatitis C
Known HIV or active hepatitis B or C infection
Chronic active or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
Known active Hepatitis B or C
Known acute or chronic hepatitis B or hepatitis C infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Patients with history of untreated hepatitis B or who are known carriers of hepatitis B will be excluded from this trial; all subjects will be screened prior to study entry
No history of chronic hepatitis B or C
Have achieved a sustained virologic response for 12 weeks after cessation of hepatitis C antiviral treatment (in HIV-positive subjects with hepatitis C)
Patients who have HIV, Hepatitis B or C
Subject has active hepatitis B or C or other active hepatic disorder.
Known clinically active infection with hepatitis B or hepatitis C virus
Ongoing or active infection, known HIV positive, known to be hepatitis B surface antigen-positive or has known or suspected active hepatitis C infection.
Active or chronic hepatitis C and/or B infection
Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted
Has active hepatitis B or hepatitis C infection, or co-infection with both hepatitis B and C virus
No active or chronic hepatitis C and/or B infection
Known active Hepatitis B or C
Participant has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined by a known positive Hepatitis C antibody result and known quantitative Hepatitis C virus (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay.
Active/uncontrolled viral hepatitis
Active hepatitis B or C infection
Untreated hepatitis B infection
Patients with known active hepatitis.
Known active Hepatitis B or C
Has known active Hepatitis B (HBV) or Hepatitis C (HCV)
Active hepatopathy of any origin including active hepatitis B and hepatitis C
Known immunodeficiency or HIV, Hepatitis B or Hepatitis C positivity.
History of human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation; HIV screening is not required for this study
Positive hepatitis B (hepatitis B surface antigen and antibody) and/or hepatitis C (hepatitis C antibody test) as indicated by serologies conducted =< 3 months prior to starting study if liver function tests are outside of the normal institutional range\r\n* NOTE: patients with hepatitis B or C serologies indicating active infection without known active disease must meet the eligibility requirements for ALT, AST, total bilirubin, INR, PTT, and alkaline phosphatase on at least two consecutive occasions, separated by at least 1 week
Has known active Hepatitis B unless subject has been on antiviral agents for at least 2 months (baseline testing not required)
Known active Hepatitis B or Hepatitis C
Active Hepatitis B or hepatitis C
Known history of chronic hepatitis B or C
Known active Hepatitis B or C
Active viral hepatitis
Individuals with active hepatitis B or C are ineligible
Known active Hepatitis B or C
Individuals with active uncontrolled hepatitis B or C are ineligible
Active hepatitis B or hepatitis C with abnormal liver function tests.
Active, uncontrolled infection, including hepatitis B, hepatitis C
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); hepatitis C infection is allowed as long as there is no active disease and is cleared by GI consultation
Evidence of active hepatitis B (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody) or active hepatitis C infection; evidence of active human immunodeficiency virus (HIV) infection
Active hepatitis B or hepatitis C
Hepatitis B or C
History of hepatitis B or C
Hepatitis B or C
Active hepatitis A, B or C
Evidence of active Hepatitis B or C or HIV
Patients with active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
All patients known to be positive for hepatitis B will be excluded from the study, and those at high risk for hepatitis B infection will be screened
Known seropositivity to human immunodeficiency virus (HIV), current acute or chronic hepatitis B (hepatitis B surface-antigen positive), hepatitis C, cirrhosis or evidence of decompensated liver disease. Patients with resolved Hepatitis B can be included.
Subjects with acute hepatitis
Known history of HIV or hepatitis C or B
Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C carrier
Known active hepatitis B or C infection
Active hepatitis A or B.
Known active Hepatitis B or Hepatitis C
History of interstitial lung disease, prior malignancy, active autoimmune disease, positive test for hepatitis B or hepatitis C virus
Patients with a known history of liver disease, autoimmune hepatitis, sclerosing cholangitis, or hepatitis B or C are not eligible for participation
Patients with known hepatitis or unstable liver disease, and/or positive serologies for Hepatitis B or C and HIV.
Active hepatitis B or hepatitis C
Known positive patients for infectious hepatitis, type A, B, C
History of HIV infection or chronic hepatitis B or C
No active hepatitis B or C infection
COHORT B: No active or chronic infection with HIV, hepatitis B or hepatitis C (negative screening tests required)
Prior, current, or chronic hepatitis B or hepatitis C infection
Subjects with confirmed Hepatitis A, B or C
Patients with active hepatitis A, hepatitis B, or hepatitis C infection
Participants with active hepatitis B, hepatitis C, or tuberculosis
Known carrier of Hepatitis B and / or Hepatitis C (whether active disease or not).
Known active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months.
Any known active liver disease. For participants who are known carriers of HBV/HCV, active hepatitis B/C infection must be ruled out per local guidelines
Active hepatitis B or hepatitis C with abnormal liver function tests.
Subject has active hepatitis B or C, or other active hepatic disorder.
No history of chronic hepatitis B or or untreated hepatitis C.
Patients with active hepatitis B or hepatitis C are excluded
Active hepatitis B infection, active hepatitis C infection
Patients with known active hepatitis (i.e. hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.
Active hepatitis B or C infection.
Active hepatitis B or C
Has a known history of Hepatitis B
Active hepatitis B or C infection
Participant has known active infection with hepatitis B or hepatitis C virus; hepatitis B and C serology testing is not required, unless active infection is suspected
Known active hepatitis B or C infection
Patients with a diagnosis of chronic hepatitis B are ineligible
HIV positive or active Hepatitis B, and/or active Hepatitis C
Active hepatitis B infection as determined by test for hepatitis B surface antigen.
Current active hepatic or biliary disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis (with exception of patients with Gilbert's syndrome and asymptomatic gallstones)
Known active viral infection\r\n* Note: viral hepatitis testing is required at screening for all patients
Active hepatitis A, B, or C infection
Chronic active hepatitis B or C.
Active or symptomatic viral hepatitis
HIV positive or active Hepatitis A or B
Active hepatitis B or hepatitis C infection
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Active hepatitis B or hepatitis C, or laboratory evidence for a chronic infection.
Clinical or laboratory evidence of active hepatitis B or hepatitis C 8. History of HIV infection.
Infection with HIV or hepatitis B or C at screening
Active infection (including HIV/acquired immune deficiency syndrome [AIDS], hepatitis B, or hepatitis C infection) requiring systemic antibiotics, antivirals, or antifungals
History of hepatitis B or C infection (subjects with evidence of cleared hepatitis B are permitted).
Patients with acute hepatitis or active infection that requires parenteral antibiotics are excluded
Severe active viral infection, especially hepatitis B.
Patients must have negative hepatitis C virus (HCV) serology; all patients must be screened for hepatitis B infection before starting treatment; those patients who test positive for hepatitis B should be closely monitored for evidence of active hepatitis B virus (HBV) infection and hepatitis during and for several months after rituximab treatment; PCNSL patients with a history of hepatitis B infection should be treated with entecavir or lamivudine (physician discretion for choice of drug) as antiviral prophylaxis to prevent hepatitis B reactivation
Patient has known historical or active infection with HIV, hepatitis B, or hepatitis C
No evidence of chronic active hepatitis or cirrhosis
Active hepatitis and/or known HIV carrier
Known active Hepatitis B or Hepatitis C virus infection
Presence of known hepatitis B or hepatitis C infection, regardless of control on antiviral therapy
Patients who are known to be HIV positive and/or have active hepatitis B or C infection
Known active hepatitis, a history of viral hepatitis B or hepatitis C
Active liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Known hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Active Hepatitis B infection as determined by test for hepatitis B surface antigen.
Previous exposure to hepatitis A or B vaccines
Current or known history of hepatitis
Known history of chronic hepatitis B or C
Known hepatitis B or hepatitis C infection or liver cirrhosis
Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
EXPANSION COHORT ONLY: Liver disease such as chronic cirrhosis, active hepatitis or chronic persistent hepatitis
No patients known to be positive for HIV, or active Hepatitis A, B, or C.
Known HIV or hepatitis A, B, or C positivity---ONLY IF ACTIVE
Subject has a chronic or acute hepatitis C infection
Subject has a chronic or acute hepatitis B infection
Has known history of or is positive for hepatitis B or hepatitis C
Active hepatitis B or C infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has known active Hepatitis B or Hepatitis C.
Active or chronic hepatitis B or hepatitis C as demonstrated by hepatitis B surface antigen positivity and/or anti- hepatitis C virus positivity, respectively. Patients with clinically active or chronic liver disease, including liver cirrhosis of Child-Pugh class C, are also excluded.
Subjects with known active hepatitis (i.e., Hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids
Active hepatitis B or C infection
Patients with acute hepatitis or active infection that requires parenteral antibiotics.
Presence of an active acute or chronic infection, including urinary tract infection, human immunodeficiency virus (HIV) or viral hepatitis HIV patients are excluded based on immunosuppression which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections; if clinically indicate HIV/viral hepatitis testing will be performed to confirm status
Active hepatitis B or C infection
Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection
Hepatitis C infection; patient may have a hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and lead associate investigator
Have uncontrolled hepatitis B or C infection
Patients known to be positive for hepatitis B or to have active hepatitis C infection;
Clinically significant active infection (e.g. tuberculosis, viral hepatitis, HIV)
Subjects with known active Hepatitis A, B or C (testing not required).
Patients with acute or chronic hepatitis
Participant with active hepatitis B or C
History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection
Known acute viral hepatitis
Active hepatitis B infection as documented by positive hepatitis B polymerase chain reaction (PCR) assay
Subjects with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy.
Positive for Hepatitis B, Hepatitis C, or HIV
Patients with known active hepatitis C are excluded
Active hepatitis A or B.
Subject has active hepatitis B or C or other active hepatic disorder.
Known active hepatitis A, B or C
Evidence of active or prior hepatitis infection.
HIV positivity (NOTE: patients positive for hepatitis B or hepatitis C are not excluded, and may be evaluated on a case-by-case basis)
Known to be positive for hepatitis B by surface antigen expression; known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months); known to be active cytomegalovirus (CMV) infection or herpes zoster infection
Patients with active viral hepatitis
Known history of active or chronic hepatitis C and/or B infection
Active evidence of hepatitis B or C infection; hepatitis B surface antigen positive
Known infection with HIV and active infection with hepatitis B or C.
Active hepatitis B or C infection as defined by seropositivity for hepatitis B (hepatitis B surface antigen [HbsAg]) or hepatitis C (hepatitis C antibody) and elevated liver transaminases (defined as above the ULN per the institution normal ranges)
Prior, current, or chronic hepatitis B or hepatitis C infection
Chronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrier
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C)
Active or chronic viral hepatitis or history of any type of hepatitis within the last 6 months
Known acute or chronic hepatitis B or C
Positive test results for chronic hepatitis BsAg infection.
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Known active or chronic hepatitis B or hepatitis C infection
Active infection including known AIDS or Hepatitis C or with a fever ?38.5°C within 3 days prior to study enrollment
Known human immunodeficiency virus (HIV) infection; patients with active hepatitis B infection (not including patients with prior hepatitis B vaccination; or positive serum hepatitis B antibody); known hepatitis C infection is allowed as long as there is no active disease and is cleared by gastrointestinal (GI) consultation
Detectable Hepatitis C virus (indicative of active Hepatitis C)
Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy.
Patients with active hepatitis
7. Subjects with known infection with hepatitis A, B or C (testing not required).
Known infection with HIV or active infection with hepatitis B or hepatitis C
Chronic active hepatitis B or C infection
Known immunodeficiency or HIV positivity, active Hepatitis B or active Hepatitis C.
Known HIV or active hepatitis B or C viral infection.
Has a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this study
Patients with hepatitis B and C will be excluded
Has known active Hepatitis B or Hepatitis C.
Active hepatitis B or C infection
Patients with hepatitis
Known HIV-positive individuals on combination antiretroviral therapy, patients with known active hepatitis B or C, or chronic hepatitis B or C requiring treatment with antiviral therapy
Chronic hepatitis with advanced, decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known viral hepatitis carrier (patient recovered from hepatitis A will be allowed to enter the study)
Current infection with HIV, Hepatitis B or Hepatitis C
Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
Subject carries a diagnosis of active hepatitis B or C
Known infection with HIV, HTLV-I, Hepatitis B, or Hepatitis C.
Participants with active hepatitis B, active hepatitis C, or active tuberculosis
Known HIV, hepatitis B or hepatitis C.
Known to be positive for hepatitis B. Known to have active hepatitis C infection or on antiviral therapy for hepatitis C within the last 6 months.
Active hepatitis B or C
Known HIV infection and/or active Hepatitis B or C infection
History of or current active infection with hepatitis B, hepatitis C or HIV
Known chronic active Hepatitis B or C, or HIV infection
Patients with chronic active hepatitis or cirrhosis; if positive hepatitis serology, the study chair may deem the patient eligible based on the results of liver biopsy
Past medical history of infection with HIV, hepatitis B or hepatitis C
Active hepatitis B or C, but participants on stable medications for hepatitis B or C.
Chronic hepatitis B or C infection.
Prior, current or chronic hepatitis B or hepatitis C infection
Subject has a known history of acute or chronic hepatitis B (HBV), HIV or hepatitis C (HCV) infection.
Chronic or active hepatitis B or C, requiring antiviral therapy
Patients known to be seropositive for hepatitis C hepatitis B
Active viral hepatitis
Known to be positive for HIV, or to have active hepatitis B, or hepatitis C, or have active infection of any kind requiring systemic therapy
Known hepatitis B surface antigen positive or known or suspected active hepatitis C infection.
Active hepatitis B infection active hepatitis C infection and/or known HIV carrier.
Chronic hepatitis B or C infection
History of any hepatitis (A,B or C)
Known to have active hepatitis C infection (positive by polymerase chain reaction or on antiviral therapy for hepatitis C within the last 6 months)
Known active hepatitis B or C
Active Hepatitis B infection in the absence of adequate antiviral therapy
Current known active infection with HIV, hepatitis B or C viruses
Evidence of hepatitis B infection
Subject has active hepatitis B or C, or other active hepatic disorder
Infection with HIV or hepatitis B or C at screening
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Chronic or active hepatitis B or C, requiring antiviral therapy
Known HIV, Hepatitis A, B or Hepatitis C infection
Active hepatitis A or B.
Known history of Hepatitis B or C infection or HIV infection
Known active Hepatitis B/ Hepatitis C/ HIV infection
Known hepatitis B surface antigen-positive, or known or suspected active hepatitis C infection
Patients with known hepatitis B or hepatitis C infection may be eligible providing they have viral load < 800,000 IU/mL within 28 days prior to registration
History of chronic active hepatitis
History of any hepatitis (A, B or C)
Known active hepatitis B or C infection
Known positive for Human Immunovirus (HIV) or infectious Hepatitis type C or active infectious Hepatitis type B.
Known active hepatitis A, B or C
History of HIV, hepatitis B, or hepatitis C
Patients with current evidence of hepatitis A, B, or C (i.e., active hepatitis)
Patient has known, active hepatic disease (ie, hepatitis B or C).
Active/chronic hepatitis B or C
Known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen positive status, or suspected active hepatitis C infection)
Known active hepatic disease (known hepatic cirrhosis, hepatitis B surface antigen positive status, or suspected active hepatitis C infection)
Active hepatitis B, hepatitis C
Known active hepatitis B, hepatitis C
Known HIV positive or Hepatitis A, B, or C infection
Known human immunodeficiency (HIV) seropositive, hepatitis C infection, and/or hepatitis B (except for patients with hepatitis B surface antigen [SAg] or core antibody receiving and responding to antiviral therapy directed at hepatitis B: these patients are allowed).
Cirrhosis or chronic active/persistent hepatitis
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Infection with HIV or hepatitis B or C at screening
Known significant chronic liver disease, such as cirrhosis or active hepatitis (potential participants who test positive for hepatitis B surface antigen or hepatitis C antibodies are allowed provided they do not have active disease requiring antiviral therapy)
Patient has known or suspected HIV, positive for hepatitis B or is known or suspected to have active hepatitis C infection.
Active hepatitis B or C viral infection
Hepatitis B or C.
Active infection including HIV, hepatitis A, B or C
Known acute or chronic hepatitis B or hepatitis C infection as determined by serologic tests
Participants who are known to have active hepatitis A, B, or C viral infection may not participate in this study; active disease is defined as participants with a known viral hepatitis whose liver function tests are elevated beyond the criteria indicated
Positive for hepatitis BsAg or HIV Ab or hepatitis C
Active hepatitis B or C infection
No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
Evidence of acute or chronic active hepatitis or cirrhosis
Hepatitis C infection; patient may have hepatitis C infection; however, each patient will require a hepatology consultation; the risk/benefit profile of transplant and hepatitis C will be discussed with the patient and eligibility determined by the principal investigator and protocol chairperson
Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis
Active hepatitis B or hepatitis C infection (hepatitis B surface antigen testing required)
Known or active HIV, viral hepatitis B or C
Chronic active hepatitis or cirrhosis
known HIV or Hepatitis
Active uncontrolled infection, including Hepatitis B, Hepatitis C infection. Patients with anti-HBc positive, or HBsAg but DNA negative are exception(s)
No currently active hepatitis B or C
Evidence of either cirrhosis or stage 3-4 liver fibrosis in patients with chronic hepatitis C or positive hepatitis C serology
Active hepatitis B or C infection
Chronic, active, or acute viral hepatitis A, B, or C infection, or a hepatitis B or C carrier
No evidence of chronic active hepatitis or cirrhosis
Active chronic hepatitis C and/or B infection
Known HIV positive, hepatitis B surface antigen positive or known or suspected active hepatitis C infection.
Has known active Hepatitis B or C
Chronic hepatitis B or C infection (e.g. hepatitis B surface antigen [Ag] positive or detectable viral load for hepatitis B or C); patients with prior evidence of hepatitis B or C without active infection are eligible
Known hepatitis B surface antigen positive, or known or suspected active hepatitis C infection.
Known positive hepatitis with evidence of active disease
Known history of HIV or active hepatitis B/C (patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible)
DONOR: Evidence of active infection or viral hepatitis
Patients with a history of chronic active hepatitis, cirrhosis or hepatic encephalopathy
Active hepatitis B (chronic or acute), or hepatitis C (exception for participants in Arm A and Arm F)
Known active clinically relevant liver disease (eg, active hepatitis B, or active hepatitis C);
Patients must be on antiviral therapy per the local standard of care if active or occult hepatitis B (hepatitis B virus [HBV]) infection; patients with active hepatitis C (hepatitis C virus [HCV]) may not be antiviral therapy
Serious concurrent illness or clinically relevant active infection, including known diagnosis of HIV and hepatitis B or C, as defined in the protocol
Active or uncontrolled clinically serious infection. (Participants with chronic viral hepatitis are eligible.)
Active hepatitis B or hepatitis C
Participants with active hepatitis B, active hepatitis C, or active tuberculosis
Known active hepatitis B or C
Patients with known history of autoimmune hepatitis, hepatitis C or those with hemoglobinopathies (e.g., thalassemia major, sickle cell anemia)
Patients with documented active hepatitis B or C infection
History of hepatitis A, B and C
Known positive for infectious hepatitis type C or active infectious hepatitis type B
Known history of HIV or active hepatitis B/C )
FOR THE 31 SUBJECTS ENROLLED IN YEAR 1: History of known active infection with HIV, hepatitis B or hepatitis C
Other known causes of significant liver disease including chronic or acute hepatitis B, acute hepatitis A, hemochromatosis, or homozygote alpha-1 antitrypsin deficiency
Evidence of any active uncontrolled infection (bacterial, viral or fungal) or evidence of natural exposure to hepatitis B, hepatitis C or human immunodeficiency virus (HIV); evidence of hepatitis B exposure includes the presence of hepatitis B surface antigenemia, a positive serological test for hepatitis B core antibody or nucleic acid testing (NAT testing) that is positive for hepatitis B; vaccination to hepatitis B is not an exclusion criteria; testing done in the pre-transplant setting is sufficient to rule out infection
Patients with a known confirmed diagnosis of HIV infection or active viral hepatitis.
Known hepatitis B or C
Known HIV or active hepatitis B or C infection
Active tuberculosis, active hepatitis, or positive HIV status
Current infection with HIV, Hepatitis B or Hepatitis C
Patient is known to be hepatitis B or hepatitis C-positive (these tests are not required)
Patients with known active hepatitis B or C
Active hepatitis B or active hepatitis C infection
Patient with active hepatitis B or C
Known history of HIV or Hepatitis C
Hepatitis B or hepatitis C active infection
Known active or chronic hepatitis B or C infection or HIV
Has a known history of Hepatitis B or known active Hepatitis C virus infection.
Active infection including tuberculosis, HIV, hepatitis B anc C
Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.
Known HIV or active hepatitis B or C viral infection
Subject has active hepatitis B or C.
Known active or chronic hepatitis B or hepatitis C infection
History of any hepatitis
Known chronic active hepatitis or cirrhosis
Any positive tests for Hepatitis B or Hepatitis C virus indicating acute or chronic infection
The patient has known active hepatitis B or C. The determination of active hepatitis B or C is left to the investigator.
Patients with hepatitis B and hepatitis C must be under the care of viral hepatitis expert consultant; patients with hepatitis B are required to be treated with anti-hepatitis B virus (HBV) treatment (e.g., entecavir); patients with hepatitis C need to have received prior and/or ongoing hepatitis C treatment
Absence of known HIV infection, chronic hepatitis B, or hepatitis C infection; absence of any other serious medical condition which could interfere with oral medication intake
Known hepatitis B surface antigen-positive or known or suspected active hepatitis C infection (testing not required).
Has known active hepatitis B or hepatitis C.
Active hepatitis B or hepatitis C
Known active viral or nonviral hepatitis